Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 747 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Motility Disorders Clear all

Conditions: Gastroesophageal Reflux Disease
Interventions: CYP2C19 genotyping; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 100 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Gainesville, Florida • Orlando, Florida

Conditions: Gastroesophageal Reflux
Interventions: IW-3718, Matching Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 10
States / cities: North Little Rock, Arkansas • Anaheim, California • Monroe, Louisiana + 7 more

Conditions: Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Esophageal Motility Disorders
Interventions: Per-oral Endoscopic Myotomy, Speedboat (Bipolar electrocautery knife); Procedure · Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: GERD
Interventions: Coffee; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pediatric Obesity, NAFLD, GERD
Interventions: Lansoprazole, Pantoprazole, Midazolam; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Years to 21 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Gastroesophageal Reflux
Interventions: Magnetic Sphincter Augmentation; Device
Lead sponsor: Torax Medical Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions: Botulinum Toxin A (Botox ), Pyloromyotomy; Biological · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions: Blood Collection, Urine Collection, Tissue Sample Collection; Diagnostic Test
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
Interventions: S-Tenatoprazole-Na (STU-Na); Drug
Lead sponsor: STEBA France; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Motility Disorder
Interventions: esophageal manometry, Gatorade, Supine position, Semi-recumbent position, Sitting, Standing; Procedure · Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Gastroesophageal Reflux
Interventions: Not listed
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Month to 5 Months
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Gastroesophageal Reflux Disease, Chronic Cough, Broncho-hyperreactivity
Interventions: Cough Reflex Sensitivity, Methacholine Challenge; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gastroesophageal Reflux, Sleeve Gastrectomy, Bariatric Surgery Complication
Interventions: EndoFLIP measurement; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Rochester, Minnesota

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
Interventions: davunetide (AL-108, NAP), Placebo nasal spray; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Esophageal Motility Disorders
Interventions: Not listed
Lead sponsor: Lexington Health Incorporated; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: West Columbia, South Carolina

Conditions: Morbid Obesity
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 2
States / cities: Sacramento, California • Reno, Nevada

Conditions: Gastroesophageal Reflux
Interventions: pantoprazole, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 28 Days to 11 Months
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 38
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more

Conditions: Amblyopia, Strabismus, Refractive Error
Interventions: Vision Screening; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 36 Months to 59 Months
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 5
States / cities: Berkeley, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions: Radiopharmaceuticals; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Airway Disease, Barrett Esophagus, Gastroesophageal Reflux Disease
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 37 Years to 90 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: GERD
Interventions: Antacids; Drug
Lead sponsor: Digestive & Liver Disease Specialists; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Acid Reflux Disease, Obstructive Sleep Apnea
Interventions: Pantoprazole; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

Monopolar and Bipolar Current RFA Knife in POEM

Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux

Effect of Obesity on Proton Pump Inhibitors

LINX Reflux Management System Clinical Study Protocol

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

Biological Sample Repository for Gastrointestinal Disorders

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

High Resolution Manometry for Swallowing

Inclined Positioning and Infant Gastroesophageal Reflux

Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction

Safety Study of TPI-287 to Treat CBS and PSP

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

Establishing a Correlation Between HRM and UGI MM Studies

Neurohumoral Control of Intestinal Electrical and Mechanical Activity

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

Vision In Preschoolers Study (VIP Study)

Tau Imaging With JNJ067

Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea